|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Net Income Loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation, amortization and impairment | |||||
| Loss on impairment of goodwill | |||||
| Equity-based compensation | |||||
| Grant receivable writeoff | |||||
| Change in fair value of warrant liability | |||||
| In-process research and development technology | |||||
| In-process research and development expense | |||||
| Changes in operating assets and liabilities: | |||||
| Grants receivable | |||||
| Prepaid expenses and other current assets | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Net cash used in operating activities | |||||
| Investing activities | |||||
| Issuance of promissory loan in connection with asset acquisition | |||||
| Cash received from asset acquisition, net of cash paid | |||||
| Net cash provided by investing activities | |||||
| Financing activities | |||||
| Proceeds from issuance of equity securities, net | |||||
| Payments on note payable | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash, cash equivalents , and restricted cash | |||||
| Cash, cash equivalents and restricted cash at beginning of period | |||||
| Cash, cash equivalents and restricted cash at end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for interest | |||||
| Insurance premium financed by note payable | |||||
| Preferred stock issued for in-process research and development technology | |||||
| Accrued issuance costs for public offering | |||||
| Settlement of promissory loans in connection with asset acquisition | |||||
| Prepaid expense financed by note payable | |||||
Loading...